STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) - USD ($) $ in Thousands	Total	Conversion Of Preferred Stock Into Common Stock	Conversion Of Convertible Notes To Common Stock	Warrants outstanding Conversion Of Preferred Stock Into Common Stock	Preferred Stock Series B Convertible Preferred	Preferred Stock Series C Convertible Preferred	Common Stock	Common Stock Conversion Of Preferred Stock Into Common Stock	Common Stock Conversion Of Convertible Notes To Common Stock	Additional Paid in Capital	Additional Paid in Capital Conversion Of Preferred Stock Into Common Stock	Additional Paid in Capital Conversion Of Convertible Notes To Common Stock	Additional Paid in Capital Warrants outstanding	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021	5,000,000
Beginning balance at Dec. 31, 2021	$ 10,000				$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2022	5,000,000
Ending balance at Dec. 31, 2022	$ 10,000				$ 0	$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2021					1,449,113	1,800,606	3,410,103
Beginning balance, equity at Dec. 31, 2021	(8,685)									$ 22,386				$ (31,071)
Stockholders’ Equity (Deficiency)
Stock-based compensation expense	1,169									1,169
Net loss	(7,582)													(7,582)
Ending balance (in shares) at Dec. 31, 2022					1,449,113	1,800,606	3,410,103
Ending balance, equity at Dec. 31, 2022	$ (15,098)									23,555				(38,653)
Series A Redeemable Convertible Preferred Stock
Conversion of preferred stock into common stock (in shares)	(5,000,000)
Conversion of preferred stock into common stock	$ (10,000)
Ending balance (in shares) at Dec. 31, 2023	0
Ending balance at Dec. 31, 2023	$ 0				$ 0	$ 0
Stockholders’ Equity (Deficiency)
Issuance of common stock and warrants in public offering (in shares)							4,485,000
Issuance of common stock and warrants in public offering	19,023						$ 1			19,022
Warrants issued to convertible note holders	159			$ 1,170						159			$ 1,170
Conversion of convertible notes into common stock (in shares)					(1,449,113)	(1,800,606)		4,124,851	1,399,716
Conversion of convertible notes into common stock		$ 10,000	$ 6,998								$ 10,000	$ 6,998
Exercise of options and warrants (in shares)							25,000
Exercise of options and warrants	50									50
Deemed dividend (in shares)							264,707
Deemed dividend	0									1,324				(1,324)
Stock-based compensation expense	1,398									1,398
Net loss	(10,538)													(10,538)
Ending balance (in shares) at Dec. 31, 2023					0	0	13,709,377
Ending balance, equity at Dec. 31, 2023	$ 13,162						$ 1			$ 63,676				$ (50,515)